The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening
Recruiting
N/A
Interventional Study
Lung Cancer
Artificial Intelligence (AI)
Randomized Controlled Trial
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 40 – 74
- Sex
- Any
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 7,294 (estimated)
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
AI diagnostic systems show great promise for improving lung cancer screening in community healthcare settings. While not originally designed for primary care, these tools demonstrate capabilities in nodule detection and workflow optimization. However, their effectiveness in resource-limited community centers requires thorough evaluation.
This RCT compares AI-assisted versus manual CT interpretati…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Aged 45-74 years
2. Permanent resident of participating study communities
3. No prior history of lung cancer and no lung cancer screening within the past 3 months
4. Able to comprehend and voluntarily sign informed consent, with willingness to participate in long-term follow-…
Contacts